BeyondSpring Inc. (BYSI)
After hours:
| Previous close | 2.4700 |
| Open | 2.4300 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 2.1700 - 2.5400 |
| 52-week range | 0.6530 - 4.0000 |
| Volume | |
| Avg. volume | 64,732 |
| Market cap | 98.736M |
| Beta (5Y monthly) | 0.25 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.5400 |
| Earnings date | 08 July 2024 - 11 July 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 1.25 |
Simply Wall St.BeyondSpring (NASDAQ:BYSI) shareholders have earned a 141% return over the last year
Unfortunately, investing is risky - companies can and do go bankrupt. But if you pick the right business to buy shares...
GlobeNewswireBeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics
FLORHAM PARK, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced that it hosted a virtual Research and Development (R&D) Day to discuss its lead asset Plinabulin, a dendritic cell (DC) maturation agent, in drug combinations to potentially address the current unmet medical needs in cancer indications where patients failed prio
- GlobeNewswire
BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics
FLORHAM PARK, N.J., May 03, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced it will host a Research and Development (R&D) Day to discuss the current unmet medical needs and the potential of Plinabulin as a novel immunochemotherapeutic in drug combinations and updates for SEED Therapeutics on Wednesday, May 15th, 2024 at 10:00 a.m. ET. T
